tebentafusp Kimmtrak
Selected indexed studies
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. (N Engl J Med, 2021) [PMID:34551229]
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. (N Engl J Med, 2023) [PMID:37870955]
- Tebentafusp (Kimmtrak) for uveal melanoma. (Med Lett Drugs Ther, 2024) [PMID:38905528]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. (2021) pubmed
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. (2023) pubmed
- Tebentafusp (Kimmtrak) for uveal melanoma. (2024) pubmed
- PMID:37903202 (2023) pubmed
- Tebentafusp: First Approval. (2022) pubmed
- PMID:38498656 (2023) pubmed
- Uveal melanoma. (2020) pubmed
- Tebentafusp. (2012) pubmed
- Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. (2024) pubmed
- Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. (2020) pubmed